Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polyinosinic polycytidylic acid - PrEP Biopharm

Next Previous
Drug Profile

Polyinosinic polycytidylic acid - PrEP Biopharm

Alternative Names: JNJ 43260295 AAM; Poly I: Poly C; Poly IC; Poly-ICLC - PrEP Biopharm; Polyinosinic-polycytidylic acid sodium salt; PrEP 001; Product Number WO 643

Latest Information Update: 05 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Developer hVIVO; Janssen Research & Development; Janssen Sciences Ireland UC; PrEP Biopharm
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Proto oncogene protein c rel modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections; Rhinovirus infections
  • Preclinical COVID 2019 infections

Most Recent Events

  • 28 Dec 2020 No recent reports of development identified for phase-I development in Rhinovirus-infections in USA (Intranasal, Spray)
  • 16 Dec 2020 Preclinical trials in COVID-2019 infections (Prevention) in United Kingdom (Intranasal)
  • 16 Dec 2020 PrEP Biopharm plans a phase IIb field trial for respiratory viruses including COVID-2019 infections, Influenza virus infections and Rhinovirus infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top